Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0003250,
umls-concept:C0005516,
umls-concept:C0018787,
umls-concept:C0034606,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0035015,
umls-concept:C0450127,
umls-concept:C0597357,
umls-concept:C1548437,
umls-concept:C1552644,
umls-concept:C1709854,
umls-concept:C1823153,
umls-concept:C1882923,
umls-concept:C2349976
|
pubmed:issue |
3
|
pubmed:dateCreated |
1989-10-13
|
pubmed:abstractText |
Anti-interleukin-2 receptor monoclonal antibodies have been shown to prevent allograft rejection. This paper reports on the biodistribution of a mouse MoAb directed at the 55 Kd alpha chain of rat interleukin-2 receptor (IL2-R) during allograft rejection. Only a low percentage (approximately 1%) of intact 125I-labeled MoAb was detected in the rejected graft, and irrelevant control IgG1 was found at a similar level. This suggests that most of the injected intact MoAb bound to graft tissue via its monomorphic Fc segment. In contrast, OX39 F(ab')2 fragments showed a preferential localization in the rejected allograft and did not bind to the LEW-to-LEW syngeneic heart graft. Irrelevant F(ab')2 did not concentrate in the allogeneic graft. Accordingly, F(ab')2 fragments from OX39 or irrelevant MoAb were used for gamma-scintigraphy on allograft recipients together with biodistribution studies. Results show that scintigraphy was able to detect allograft accumulation of 131I OX39 F(ab')2, whereas no imaging was obtained when OX39 F(ab')2 was used in the syngeneic combination or when irrelevant 131-IgG1 F(ab')2 was given to allograft recipients. This method, applied to the clinical situation, could be of interest for detection of early graft rejection episodes by immunoscintigraphy using reagents specific for activation determinants on lymphocyte membranes, such as anti-interleukin-2 receptor MoAb.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0041-1337
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
48
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
367-71
|
pubmed:dateRevised |
2005-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2675394-Animals,
pubmed-meshheading:2675394-Antibodies, Monoclonal,
pubmed-meshheading:2675394-Graft Rejection,
pubmed-meshheading:2675394-Heart Transplantation,
pubmed-meshheading:2675394-Immunoglobulin Fab Fragments,
pubmed-meshheading:2675394-Lymphocyte Activation,
pubmed-meshheading:2675394-Radionuclide Imaging,
pubmed-meshheading:2675394-Rats,
pubmed-meshheading:2675394-Receptors, Interleukin-2,
pubmed-meshheading:2675394-T-Lymphocytes
|
pubmed:year |
1989
|
pubmed:articleTitle |
Biodistribution of an anti-interleukin 2 receptor monoclonal antibody in rat recipients of a heart allograft, and its use as a rejection marker in gamma scintigraphy.
|
pubmed:affiliation |
Institut National Pour la Recherche Scientifique et Médicale U.211, Unité de recherche sur les effecteurs lymphocytaires T, Faculté de Médecine, Nantes, France.
|
pubmed:publicationType |
Journal Article
|